Tuesday’s packed schedule will let attendees hear from Anders Tveteraas, international head of patient solutions and services at Novartis and Julie Anderson, principal, behavioural health s
From Akili’s transition to over-the-counter to the downfall of Pear Therapeutics, it’s been an exciting time lately in the world of digital therapeutics.
Problems at a contract manufacturing organisation have scuppered Eli Lilly’s hopes of a timely FDA approval for lebrikizumab, its IL-13 inhibitor for the treatment of atop
Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho